Cardinal Capital Management Bristol Myers Squibb CO Transaction History

Cardinal Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	SELL	$40.25 - $52.99 $2.29 Million - $3.01 Million	-56,860 Closed	0 $0
Q1 2024 Jul 12, 2024	BUY	$47.98 - $54.4 $297,955 - $337,824	6,210 Added 12.26%	56,860 $3.08 Million
Q1 2024 Apr 15, 2024	BUY	$47.98 - $54.4 $297,955 - $337,824	6,210 Added 12.26%	56,860 $3.08 Million
Q4 2023 Jul 12, 2024	BUY	$48.48 - $57.85 $731,417 - $872,782	15,087 Added 42.42%	50,650 $2.6 Million
Q4 2023 Jan 26, 2024	BUY	$48.48 - $57.85 $731,417 - $872,782	15,087 Added 42.42%	50,650 $2.6 Million
Q3 2023 Jul 12, 2024	BUY	$57.89 - $64.73 $61,942 - $69,261	1,070 Added 3.1%	35,563 $2.06 Million
Q3 2023 Oct 16, 2023	BUY	$57.89 - $64.73 $61,942 - $69,261	1,070 Added 3.1%	35,563 $2.06 Million
Q2 2023 Jul 12, 2024	SELL	$63.71 - $70.74 $1.43 Million - $1.58 Million	-22,367 Reduced 39.34%	34,493 $2.21 Million
Q2 2023 Jul 12, 2023	BUY	$63.71 - $70.74 $2.2 Million - $2.44 Million	34,493 New	34,493 $2.21 Million

2,407

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $115B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Cardinal Capital Management, based on Form 13F filings with the SEC.

Stay updated on Cardinal Capital Management with notifications on news.